Literature DB >> 8265360

Cloning and expression of the hypoxanthine-guanine phosphoribosyltransferase gene from Trypanosoma brucei.

T E Allen1, B Ullman.   

Abstract

The hypoxanthine-guanine phosphoribosyltransferase (HGPRT) enzyme of Trypanosoma brucei and related parasites provides a rational target for the treatment of African sleeping sickness and several other parasitic diseases. To characterize the T. brucei HGPRT enzyme in detail, the T. brucei hgprt was isolated within a 4.2 kb SalI-KpnI genomic insert and sequenced. Nucleotide sequence analysis revealed an open reading frame of 630 bp that encoded a protein of 210 amino acids with a M(r) = 23.4 kd. After gap alignment, the T. brucei HGPRT exhibited 21-23% amino acid sequence identity, mostly in three clustered regions, with the HGPRTs from human, S. mansoni, and P falciparum, indicating that the trypanosome enzyme was the most divergent of the group. Surprisingly, the T. brucei HGPRT was more homologous to the hypoxanthine phosphoribosyltransferase (HPRT) from the prokaryote V. harveyi than to the eukaryotic HGPRTs. Northern blot analysis revealed two trypanosome transcripts of 1.4 and 1.9 kb, each expressed to equivalent degrees in insect vector and mammalian forms of the parasite. The T. brucei hgprt was inserted into an expression plasmid and transformed into S phi 606 E. coli that are deficient in both HPRT and xanthine-guanine phosphoribosyltransferase activities. Soluble, enzymatically active recombinant T. brucei HGPRT was expressed to high levels and purified to homogeneity by GTP-agarose affinity chromatography. The purified recombinant enzyme recognized hypoxanthine, guanine, and allopurinol, but not xanthine or adenine, as substrates and was inhibited by a variety of nucleotide effectors. The availability of a molecular clone encoding the T. brucei hgprt and large quantities of homogeneous recombinant HGPRT enzyme provides an experimentally manipulable molecular and biochemical system for the rational design of novel therapeutic agents for the treatment of African sleeping sickness and other diseases of parasitic origin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8265360      PMCID: PMC310582          DOI: 10.1093/nar/21.23.5431

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  47 in total

1.  The role of polyamines in the neutralization of bacteriophage deoxyribonucleic acid.

Authors:  B N AMES; D T DUBIN
Journal:  J Biol Chem       Date:  1960-03       Impact factor: 5.157

2.  High level expression in Escherichia coli of soluble, enzymatically active schistosomal hypoxanthine/guanine phosphoribosyltransferase and trypanosomal ornithine decarboxylase.

Authors:  S P Craig; L Yuan; D A Kuntz; J H McKerrow; C C Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

3.  Nucleotide sequence of the Leishmania donovani medRNA gene.

Authors:  K Wilson; S Hanson; S Landfear; B Ullman
Journal:  Nucleic Acids Res       Date:  1991-10-25       Impact factor: 16.971

4.  A purine nucleoside hydrolase from Trypanosoma gambiense, purification and properties.

Authors:  G Schmidt; R D Walter; E Königk
Journal:  Tropenmed Parasitol       Date:  1975-03

5.  Prediction of protein conformation.

Authors:  P Y Chou; G D Fasman
Journal:  Biochemistry       Date:  1974-01-15       Impact factor: 3.162

6.  Trypanosome ornithine decarboxylase is stable because it lacks sequences found in the carboxyl terminus of the mouse enzyme which target the latter for intracellular degradation.

Authors:  L Ghoda; M A Phillips; K E Bass; C C Wang; P Coffino
Journal:  J Biol Chem       Date:  1990-07-15       Impact factor: 5.157

7.  Amplification and molecular cloning of the ornithine decarboxylase gene of Leishmania donovani.

Authors:  S Hanson; J Adelman; B Ullman
Journal:  J Biol Chem       Date:  1992-02-05       Impact factor: 5.157

8.  Location on the chromosome of Escherichia coli of genes governing purine metabolism. Adenosine deaminase (add), guanosine kinase (gsk) and hypoxanthine phosphoribosyltransferase (hpt).

Authors:  B Jochimsen; P Nygaard; T Vestergaard
Journal:  Mol Gen Genet       Date:  1975-12-30

9.  Allopurinol in the treatment of American cutaneous leishmaniasis.

Authors:  S Martinez; J J Marr
Journal:  N Engl J Med       Date:  1992-03-12       Impact factor: 91.245

10.  Purine salvage networks in Giardia lamblia.

Authors:  C C Wang; S Aldritt
Journal:  J Exp Med       Date:  1983-11-01       Impact factor: 14.307

View more
  4 in total

1.  Preliminary structural studies on the multi-ligand-binding domain of the transcription activator, BmrR, from Bacillus subtilis.

Authors:  E E Zheleznova; P N Markham; A A Neyfakh; R G Brennan
Journal:  Protein Sci       Date:  1997-11       Impact factor: 6.725

2.  First report of molecular characterization and phylogenetic analysis of RoTat 1.2 VSG of Trypanosoma evansi from equine isolate.

Authors:  Vikrant Sudan; Amit Kumar Jaiswal; Daya Shanker; Amit Kumar Verma
Journal:  Trop Anim Health Prod       Date:  2017-08-22       Impact factor: 1.559

3.  Trypanosoma brucei adenine-phosphoribosyltransferases mediate adenine salvage and aminopurinol susceptibility but not adenine toxicity.

Authors:  Alexandra Lüscher; Estelle Lamprea-Burgunder; Fabrice E Graf; Harry P de Koning; Pascal Mäser
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2013-12-19       Impact factor: 4.077

4.  Evaluation of the Trypanosoma brucei 6-oxopurine salvage pathway as a potential target for drug discovery.

Authors:  Eva Doleželová; David Terán; Ondřej Gahura; Zuzana Kotrbová; Michaela Procházková; Dianne Keough; Petr Špaček; Dana Hocková; Luke Guddat; Alena Zíková
Journal:  PLoS Negl Trop Dis       Date:  2018-02-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.